| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLCO4C1 |
| Uniprot No | Q6ZQN7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-724 aa |
| 活性数据 | MKSAKGIENLAFVPSSPDILRRLSASPSQIEVSALSSDPQRENSQPQELQKPQEPQKSPEPSLPSAPPNVSEEKLRSLSLSEFEEGSYGWRNFHPQCLQRCNTPGGFLLHYCLLAVTQGIVVNGLVNISISTVEKRYEMKSSLTGLISSSYDISFCLLSLFVSFFGERGHKPRWLAFAAFMIGLGALVFSLPQFFSGEYKLGSLFEDTCVTTRNSTSCTSSTSSLSNYLYVFILGQLLLGAGGTPLYTLGTAFLDDSVPTHKSSLYIGTGYAMSILGPAIGYVLGGQLLTIYIDVAMGESTDVTEDDPRWLGAWWIGFLLSWIFAWSLIIPFSCFPKHLPGTAEIQAGKTSQAHQSNSNADVKFGKSIKDFPAALKNLMKNAVFMCLVLSTSSEALITTGFATFLPKFIENQFGLTSSFAATLGGAVLIPGAALGQILGGFLVSKFRMTCKNTMKFALFTSGVALTLSFVFMYAKCENEPFAGVSESYNGTGELGNLIAPCNANCNCSRSYYYPVCGDGVQYFSPCFAGCSNPVAHRKPKVYYNCSCIERKTEITSTAETFGFEAKAGKCETHCAKLPIFLCIFFIVIIFTFMAGTPITVSILRCVNHRQRSLALGIQFMVLRLLGTIPGPIIFGFTIDSTCILWDINDCGIKGACWIYDNIKMAHMLVAISVTCKVITMFFNGFAIFLYKPPPSATDVSFHKENAVVTNVLAEQDLNKIVKEG |
| 分子量 | 106.59 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SLCO4C1蛋白的3条参考文献的简要概述：
---
1. **文献名称**: *"Recombinant human SLCO4C1 transporter expressed in HEK293 cells mediates organic anion uptake"*
**作者**: Toyohara T, et al.
**摘要**: 该研究利用HEK293细胞成功表达了重组人SLCO4C1蛋白，并证实其作为有机阴离子转运体的功能，可介导尿毒症毒素(如胍丁二酸)的摄取。研究表明，SLCO4C1可能在慢性肾脏病的毒素清除中具有潜在治疗价值。
---
2. **文献名称**: *"SLCO4C1 downregulation reduces hypertensive nephropathy by enhancing toxin excretion"*
**作者**: Aoki M, et al.
**摘要**: 通过高血压大鼠模型，发现SLCO4C1在肾脏中的表达受盐摄入量调节。抑制SLCO4C1活性可促进尿毒症毒素排出，减轻肾脏纤维化，提示其作为高血压相关肾损伤的治疗靶点。
---
3. **文献名称**: *"Drug interaction potential of recombinant SLCO4C1: Focus on uremic toxin transport"*
**作者**: Miyauchi S, et al.
**摘要**: 研究利用重组SLCO4C1蛋白分析了多种药物与其转运活性的相互作用，发现部分心血管药物可能竞争性抑制SLCO4C1的功能，从而影响尿毒症毒素的代谢动力学，为临床用药提供参考。
---
上述文献涵盖SLCO4C1的分子功能、疾病关联及药物相互作用，均通过重组蛋白模型揭示其在毒素清除和肾脏病理中的关键作用。
SLCO4C1. a member of the solute carrier organic anion transporter (SLCO) family, is a transmembrane protein involved in the transport of endogenous compounds and xenobiotics. It encodes the organic anion transporter 4C1 (OATP4C1), primarily expressed in the kidney, where it localizes to the basolateral membrane of proximal tubule cells. Structurally, it contains 12 transmembrane domains and facilitates sodium-independent uptake of substrates, including thyroid hormones, uremic toxins (e.g., cAMP, cortisol), and clinically relevant drugs like digoxin and methotrexate. Its role in renal clearance highlights its importance in maintaining systemic homeostasis and detoxification.
Research links SLCO4C1 dysfunction to chronic kidney disease (CKD), as reduced expression correlates with impaired toxin excretion and disease progression. Notably, OATP4C1 overexpression in rodent models ameliorates CKD symptoms by enhancing toxin removal. Pharmacologically, SLCO4C1 influences drug pharmacokinetics, with genetic polymorphisms potentially altering therapeutic efficacy or toxicity risks. Recombinant SLCO4C1 proteins are engineered to study substrate specificity, transport mechanisms, and interactions with therapeutic agents. These studies aid in predicting drug-drug interactions and optimizing dosing regimens, particularly in patients with renal impairment. Emerging therapeutic strategies target SLCO4C1 to enhance toxin clearance or modulate drug transport, underscoring its clinical relevance in nephrology and precision medicine.
×
